Drug Trial Radar · NCT06873542
A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Jul 8, 2022
Primary completion
Dec 7, 2022
Study completion Jan 2, 2024
Sponsor
- Lead sponsor
- Heronova PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial employs a non-randomized, open-label, dose-escalation design to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of DC05F01 in Chinese patients with advanced or metastatic solid tumors.
Conditions
- Solid Tumors
Interventions
DC05F01Drug
DC05F01 capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse EventsTime frame: 6 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Shandong Cancer Hospital
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.